Drug
Opb 201
Opb 201: highest development phase Phase 1, developed by Outpace Bio, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Outpace Bio, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| OPB-201 NCT07664735 | Phase 1 | Endometrial Cancer Recurrent |
Latest
No recent events.
Follow Opb 201 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.